个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Wang, F.[1] * ; Xiao, J.[2] ; Zhang, Y.[2,3] ; Yuan, X.[4] ; He, M. ; Fang, W.[5] ; Zhang, Y.[2,3] ; Wang, W.[6] ; Hu, X.[7] ; Ma, Z.[3] ; Yao, Y.[1] ; Zhuang, Z.[8] ; Zhou, F.[9] ; Ying, J.[10] ; Yuan, Y.[11] ; Zou, Q.[12] ; Guo, Z.[13] ; Wu, X.[14] ; Jin, Y.[1] ; Mai, Z.[1] ; Guo, Y.[1] ; Xu, R.[15] ;
单位： [1]Sun Yat sen Univ Canc Ctr, Guangzhou, Peoples R China [2]Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China [3]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [4]Huazhong Univ Sci & Technol, Tongji Hosp, Shanghai, Peoples R China [5]Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China [6]Peoples Hosp Foshan 1, Foshan, Peoples R China [7]Guangxi Med Univ, Affiliated Hosp 1, Guangxi, Peoples R China [8]Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R China [9]Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China [10]Zhejiang Canc Hosp, Hangzhou, Peoples R China [11]Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China [12]Guangzhou Med Univ, Tumor Hosp, Guangzhou, Peoples R China [13]Fujian Canc Hosp, Fuzhou, Peoples R China [14]Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China [15]Sun Yat Sen Univ, Med Oncol Canc Ctr, Guangzhou, Peoples R China
出处：
DOI： 10.1016/j.annonc.2022.04.416
ISSN：
基金：
Sun Yat-sen University Clinical Research 5010 Program [2018014]; National Natural Science Foundation of China [81930065, 82173128]; Science and Technology Program of Guangdong [2019B020227002]; Science and Technology Program of Guangzhou [201904020046]
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2020]版：
Q1 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者单位： [1]Sun Yat sen Univ Canc Ctr, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Wang F.,Xiao J.,Zhang Y.,et al.A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer[J].ANNALS OF ONCOLOGY.2022,33:S364-S364.doi:10.1016/j.annonc.2022.04.416.
APA：
Wang, F.,Xiao, J.,Zhang, Y.,Yuan, X.,He, M....&Xu, R..(2022).A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer.ANNALS OF ONCOLOGY,33,
MLA：
Wang, F.,et al."A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer".ANNALS OF ONCOLOGY 33.(2022):S364-S364

资源点击量：622 今日访问量：0 总访问量：452 更新日期：2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）